Positioning infliximab and vedolizumab in the treatment of moderate-to-severe ulcerative colitis. Sheehan JL, Cohen-Mekelburg S. Gastroenterology 2021 Dec 2. pii: S0016-5085(21)03815.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sheehan JL, Cohen-Mekelburg S. Positioning infliximab and vedolizumab in the treatment of moderate-to-severe ulcerative colitis. Gastroenterology 2021 Dec 2. pii: S0016-5085(21)03815.
PMID: 34864070